New drugs and dosage forms

March 2011
American Journal of Health-System Pharmacy;3/1/2011, Vol. 68 Issue 5, p366
Academic Journal
The article provides information on dosage forms of the drugs, Ioflupane 1123 (DaTscan, GE Healthcare) and Spinosad (Natroba, Parapro).


Related Articles

  • Molecular Imaging and Contrast Agent Database (MICAD): Evolution and Progress. Chopra, Arvind; Shan, Liang; Eckelman, W.; Leung, Kam; Latterner, Martin; Bryant, Stephen; Menkens, Anne // Molecular Imaging & Biology;Feb2012, Vol. 14 Issue 1, p4 

    The purpose of writing this review is to showcase the Molecular Imaging and Contrast Agent Database (MICAD; ) to students, researchers, and clinical investigators interested in the different aspects of molecular imaging. This database provides freely accessible, current, online scientific...

  • PET-MRI in the head and neck area: challenges and new directions. Castelijns, J. // European Radiology;Nov2011, Vol. 21 Issue 11, p2425 

    The article discusses the challenges and trends on the use of positron emission tomography-magnetic resonance imaging (PET-MRI) in head and neck pathology. It says that the images obtained with PET-MRI system show better detailed resolution and greater image contrast as compared to those from...

  • The effect of integrating contrast enhanced CT in FDG PET/CT imaging of Extrapulmonary Tuberculosis patients: preliminary data. Hairil Rashmizal Abdul Razak; Moshi Geso; Noraini Abdul Rahim; Abdul Jalil Nordin // ANZ Nuclear Medicine;Dec2010, Vol. 41 Issue 4, p19 

    Purpose of the report : The main goal of this study was to evaluate the effects of the application of intravenous (IV) iodine contrast media on semiquantitative values of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) imaging in Extrapulmonary Tuberculosis...

  • Quantitative Effects of Contrast Enhanced CT Attenuation Correction on PET SUV Measurements. Tira Bunyaviroch; Timothy Turkington; Terence Wong; John Wilson; James Colsher; R. Coleman // Molecular Imaging & Biology;Mar2008, Vol. 10 Issue 2, p107 

    Abstract Purpose  The presence of contrast materials on computed tomography (CT) images can cause problems in the attenuation correction of positron emission tomography (PET) images. These are because of errors converting the CT attenuation of contrast to 511-keV attenuation and...

  • Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? Mayerhoefer, Marius; Schuetz, Matthias; Magnaldi, Silvia; Weber, Michael; Trattnig, Siegfried; Karanikas, Georgios // European Radiology;Apr2012, Vol. 22 Issue 4, p938 

    Objectives: To determine the value of intravenous contrast medium in (68)Ga-DOTA-Phe(1)-Tyr(3)-octreotide - (68)Ga-DOTATOC - PET/CT for the detection of abdominal neuroendocrine tumours (NET). Methods: In fifty-five patients with known or suspected NETs of the abdomen PET/CT was performed on a...

  • Beyond FDG: Many Molecular Imaging Agents Are in Development. Brower, Vicki // JNCI: Journal of the National Cancer Institute;Jan2011, Vol. 103 Issue 1, p13 

    The article discusses the development of molecular imaging agents designed to visualize detailed tumor-specific characteristics. It provides an overview of a study on the use of the standard fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging. The advantages of molecular imaging...

  • Sleeping Trojan Horse to Aid Imaging of Diseased Cells.  // Biotechnology;2011, Vol. 10 Issue 2, p227 

    No abstract available.

  • Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Pfannenberg, Anna C.; Aschoff, Philip; Brechtel, Klaus; Müller, Mark; Bares, Roland; Paulsen, Frank; Scheiderbauer, Jutta; Friedel, Godehard; Claussen, Claus D.; Eschmann, Susanne M. // European Journal of Nuclear Medicine & Molecular Imaging;Jan2007, Vol. 34 Issue 1, p36 

    To evaluate low dose non-enhanced CT and standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning of non-small cell lung cancer (NSCLC). Retrospective analysis was performed of 50 consecutive patients with proven NSCLC who had been referred for primary...

  • Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives. Hahn, Megan A.; Singh, Amit K.; Sharma, Parvesh; Brown, Scott C.; Moudgil, Brij M. // Analytical & Bioanalytical Chemistry;Jan2011, Vol. 399 Issue 1, p3 

    Nanoparticle-based contrast agents are quickly becoming valuable and potentially transformative tools for enhancing medical diagnostics for a wide range of in-vivo imaging modalities. Compared with conventional molecular-scale contrast agents, nanoparticles (NPs) promise improved abilities for...

  • Integrated 18F-Fluorodeoxyglucose-Positron Emission Tomography/Dynamic Contrast-Enhanced Computed Tomography to Phenotype Non-Small Cell Lung Carcinoma. Shastry, Manu; Miles, Kenneth A.; Win, Thida; Janes, Sam M.; Endozo, Raymond; Meagher, Marie; Ell, Peter J.; Groves, Ashley M. // Molecular Imaging;Sep/Oct2012, Vol. 11 Issue 5, p353 

    We applied modern molecular and functional imaging to the pretreatment assessment of lung cancer using combined dynamic contrast-enhanced computed tomography (DCE-CT) and 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) to phenotype tumors. Seventy-four lung cancer patients were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics